Evaluating Mucilage from Aloe Barbadensis Miller as a Pharmaceutical Excipient for Sustained-Release Matrix Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Evaluating Mucilage from Aloe Barbadensis Miller as a Pharmaceutical Excipient for Sustained-Release Matrix Tablets
Natural gums and mucilage have been widely explored as pharmaceutical excipients. The goal of this study was to extract mucilage from the leaves of Aloe barbadensis Miller and to study its functionality as an excipient in pharmaceutical sustained-release tablet formulations.


Pharmaceutical Technology


20. M.E. Aulton, Pharmaceutics: The Science of Dosage Form Design, (Churchill Livingstone, London, 2nd ed.), pp. 133–135.

21. Ministry of Health and Family Welfare, Government of India. Indian Pharmacopoeia (The Controller of Publications, New Delhi, 4th ed., 1996), pp. A-114–116.

22. S.B Gilbert and R.A. Neil, "Tablets" in The Theory and Practice of Industrial Pharmacy, L. Lachman, H.A. Libermann, and J.L. Kanig Eds., (Varghese Publishing House, Bombay, India 3rd ed., 1987), pp. 293–344.

23. R. Ilango et al., "In-vitro Studies on Buccal Strips of Glibenclamide using Chitosan," Indian J. Pharm. Sci. 59 (5), 232–235 (1997).

24. P. Colombo et al., "Drug Release Modulation by Physical Restriction of Matrix Swelling," Int. J. Pharm. 63 (1), 43–48 (1990).

25. P.D. Bharadia and M.C. Gohel, "Formulation and Evaluation of Diclofenac Sodium Modified Release using Ispaghula Husk," The Indian Pharmacist 5 (51), 92–96 (2006).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here